Author

Morten Asser Karsdal

A NEO-EPITOPE SPECIFIC BIOMARKER OF FIBROSIS RESOLUTION - DETECTION OF PROTEASE DEGRADED, AND CROSS-LINKED TYPE III COLLAGEN DEGRADATION METABOLITES RELEASED WITH FIBROLYSIS
A NEO-EPITOPE SPECIFIC BIOMARKER OF FIBROSIS RESOLUTION - DETECTION OF PROTEASE DEGRADED, AND CROSS-LINKED TYPE III COLLAGEN DEGRADATION METABOLITES RELEASED WITH FIBROLYSIS

Morten Asser Karsdal  et al.

HUMAN NEUTROPHIL ELASTASE DERIVED FRAGMENT OF CALPROTECTIN (S100A9) IS A SERUM BIOMARKER (CPA9-HNE) FOR MONITORING OF ANTI-TNFA TREATMENT RESPONSE IN CROHN’S DISEASE
HUMAN NEUTROPHIL ELASTASE DERIVED FRAGMENT OF CALPROTECTIN (S100A9) IS A SERUM BIOMARKER (CPA9-HNE) FOR MONITORING OF ANTI-TNFA TREATMENT RESPONSE IN CROHN’S DISEASE

Morten Asser Karsdal  et al.

BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE
BIOMARKERS OF EXTRACELLULAR MATRIX TURNOVER AND NEUTROPHIL ACTIVITY PREDICT LONG-TERM RESPONSE TO VEDOLIZUMAB IN PATIENTS WITH CROHN’S DISEASE

Morten Asser Karsdal  et al.

SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SEROLOGICAL BIOMARKERS OF TYPE III AND IV COLLAGEN REMODELING PREDICT AND MONITOR INFLIXIMAB TREATMENT RESPONSE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Morten Asser Karsdal  et al.

BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY
BIOMARKERS REFLECTING EXTRACELLULAR MATRIX TURNOVER AND INFLAMMATION CAN BE USED TO MONITOR DISEASE ACTIVITY AND TREATMENT RESPONSE IN PATIENTS WITH CROHN’S DISEASE UNDERGOING INFLIXIMAB INDUCTION THERAPY

Morten Asser Karsdal  et al.

NOVEL SEROLOGICAL BIOMARKERS FOR MONITORING DISEASE PROGRESSION IN ADULT EOSINOPHILIC ESOPHAGITIS PATIENTS
NOVEL SEROLOGICAL BIOMARKERS FOR MONITORING DISEASE PROGRESSION IN ADULT EOSINOPHILIC ESOPHAGITIS PATIENTS

Morten Asser Karsdal  et al.

NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR
NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR

Morten Asser Karsdal  et al.

A MARKER OF PROTEOLYTIC DEGRADATION OF CROSS-LINKED TYPE V COLLAGEN IS UPREGULATED IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
A MARKER OF PROTEOLYTIC DEGRADATION OF CROSS-LINKED TYPE V COLLAGEN IS UPREGULATED IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Morten Asser Karsdal  et al.

NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD
NEO-EPITOPE PROTEIN FRAGMENT OF CALPROTECTIN DERIVED FROM HUMAN NEUTROPHIL ELASTASE (CPA9-HNE) IS A NOVEL SERUM CALPROTECTIN BIOMARKER OF INFLAMMATION AND DISEASE ACTIVITY FOR IBD

Morten Asser Karsdal  et al.

TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
TYPE I COLLAGEN DEGRADATION FRAGMENTS (C1M) AND HUMAN NEUTROPHIL ELASTASE-DERIVED FRAGMENTS OF CALPROTECTIN (CPA9-HNE) REFLECT BIOCHEMICAL AND ENDOSCOPIC DISEASE ACTIVITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Morten Asser Karsdal  et al.

ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY
ENDOTROPHIN (PRO-C6) IS ASSOCIATED WITH MRE CONFIRMED INTESTINAL STRICTURES AND PROTEIN FINGERPRINT BIOMARKERS OF COLLAGEN DEGRADATION IS ASSOCIATED WITH ULCERATIONS IN PAEDIATRIC CROHN’S DISEASE PATIENTS – RESULTS FROM THE IMAGEKIDS STUDY

Morten Asser Karsdal  et al.

SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE
SEROLOGICAL BIOMARKERS OF TYPE I, III, AND IV COLLAGEN TURNOVER ARE ASSOCIATED WITH THE PRESENCE AND FUTURE PROGRESSION OF STRICTURING AND PENETRATING CROHN'S DISEASE

Morten Asser Karsdal  et al.

TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS
TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO PREDICTS RESPONSE TO INFLIXIMAB INDUCTION THERAPY IN PATIENTS WITH ULCERATIVE COLITIS

Morten Asser Karsdal  et al.

TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE
TYPE I, III, AND IV COLLAGEN DEGRADATION FRAGMENTS AND THE TYPE IV COLLAGEN FORMATION/DEGRADATION RATIO ARE SEROLOGICAL BIOMARKERS FOR STRICTURING (MONTREAL B2) CROHN'S DISEASE

Morten Asser Karsdal  et al.

Item 1 - 14 / 14
1